Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection
| Autor: | Ivana Bjelogrlic, Lejla Mehinovic, Aleksandra Djurovic, Amila Mehmedovic, Zora Vukobrat-Bijedic, Amela Sofic, Dzelaludin Junuzovic, Azra Husic-Selimovic |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Original Paper
medicine.medical_specialty Cirrhosis business.industry Hepatitis C virus Standard treatment Ribavirin virus diseases Retrospective cohort study medicine.disease medicine.disease_cause Regression chemistry.chemical_compound Chronic infection Antiviral Therapy chemistry Fibrosis Internal medicine Immunology medicine Steatosis business |
| Zdroj: | Materia Socio-Medica |
| ISSN: | 1512-7680 |
| DOI: | 10.5455/msm.2014.26.172-176 |
| Popis: | Background: HCV infection is characterized by a tendency towards chronicity. Acute HCV infection progresses to chronic infection in 70% of cases. Hepatitis C virus infection can cause progressive liver injury and lead to fibrosis and eventually cirrhosis. The degree of histologic fibrosis is an important marker of the stage of the disease. One of current standard treatment for CHC infection is the combination of PEG-IFN α and ribavirin. Objectives: The aim of the study was to investigate the effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver fibrosis in patients with chronic hepatitis C. Also, our aim was to examine whether there was a difference between the genders in the efficacy of these antiviral therapy. Our goal also was to determine effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver steatosis in patients with chronic hepatitis C. Patients and Methods: A retrospective study was made of chronic hepatitis C patients who had been treated from 2005 to April 2014 at the Clinic of Gastroenterohepatology, Clinical Center University of Sarajevo. We reviewed 40 patient medical records to collect demographic, epidemiological and clinical information, as information on liver biopsies that was performed prior to the antiviral therapy and FibroScan® test that was performed after the antiviral therapy. For the processing of data SPSS (Statistical Package for the Social Sciences Program) for Windows, ver. 21.0 statistical software was used. Comparisons between qualitative and quantitative variables were performed using the Student t-test. Mann Whitney U test was used to compare differences in variables such as fibrosis stage and steatosis grade. A value of p0.05). There was significantly higher decrease of fibrosis progression at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction. We found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p< 0.05). We also found significant association in evolution of steatosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p < 0.05). There was statistically significant differences (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|